At 10.8% CAGR, the Europe Radiopharmaceutical Theranostics Market is projected to be worth US$ 853.61 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe radiopharmaceutical theranostics market was valued at US$ 462.25 million in 2022 and is expected to reach US$ 853.61 million by 2028, registering a CAGR of 10.8% from 2022 to 2028. Rising incidence of cancer and rising application in treatment of cardiovascular disorders are the critical factors attributed to the Europe radiopharmaceutical theranostics market expansion.             

Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels.

A National Institute of Health (NIH) report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients. This is expected to drive the Europe radiopharmaceutical theranostics market during the forecast period.

On the contrary, regulatory challenges for approval of radiopharmaceutical theranostics hurdles the growth of Europe radiopharmaceutical theranostics market. 

Based on product type, the Europe radiopharmaceutical theranostics market is categorized into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The positron emission tomography (PET) tracers segment held 46.9% market share in 2022, amassing US$ 216.64 million. It is projected to garner US$ 411.84 million by 2028 to expand at 11.3% CAGR during 2022–2028.

Based on radioisotope, the Europe radiopharmaceutical theranostics market is categorized into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18 (18F), yttrium 90 (Y-90), Lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held 25.4% market share in 2022, amassing US$ 117.54 million. It is projected to garner US$ 230.02 million by 2028 to expand at 11.8% CAGR during 2022–2028.

Based on source, the Europe radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held 60.5% market share in 2022, amassing US$ 279.51 million. It is projected to garner US$ 546.14 million by 2028 to expand at 11.8% CAGR during 2022–2028.

Based on application, the Europe radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held 64.4% market share in 2022, amassing US$ 297.49 million. It is projected to garner US$ 556.74 million by 2028 to expand at 11.0% CAGR during 2022–2028.

Based on indication, the Europe radiopharmaceutical theranostics market is categorized into oncology, cardiology, neurology, and others. The oncology segment held 63.9% market share in 2022, amassing US$ 295.15 million. It is projected to garner US$ 564.03 million by 2028 to expand at 11.4% CAGR during 2022–2028.

Based on end user, the Europe radiopharmaceutical theranostics market is categorized into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held 35.0% market share in 2022, amassing US$ 161.75 million. It is projected to garner US$ 293.82 million by 2028 to expand at 10.5% CAGR during 2022–2028.

Based on country, the Europe radiopharmaceutical theranostics market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe.  Our regional analysis states that Germany captured 29.9% share of Europe radiopharmaceutical theranostics market in 2022. It was assessed at US$ 137.98 million in 2022 and is likely to hit US$ 266.33 million by 2028, exhibiting a CAGR of 11.6% during the forecast period.            

Key players dominating the Europe radiopharmaceutical theranostics market are Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; and Theragnostics among others.

• In Jun 2022, Curium Acquires Austrian Radiopharmaceuticals Company IASON.
• In Jun 2022, Lantheus’ PYLARIFY AI Platform Demonstrates Higher Efficiency and Consistency.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com